Patents by Inventor Punit P. Seth

Punit P. Seth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF
    Publication number: 20170327824
    Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount, activity, or expression of the target nucleic acid in a cell. In certain embodiments, hybridization results in selective modulation of the amount, activity, or expression of a target Huntingtin gene or Huntingtin transcript in a cell.
    Type: Application
    Filed: March 24, 2017
    Publication date: November 16, 2017
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Michael Oestergaard, Punit P. Seth, Eric E. Swayze
  • ANTISENSE COMPOUNDS AND USES THEREOF
    Publication number: 20170283804
    Abstract: The present disclosure provides methods for sensitizing a cell for modulation by oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.
    Type: Application
    Filed: September 21, 2015
    Publication date: October 5, 2017
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Erich Koller, Aaron J. Donner, Punit P. Seth, C. Frank Bennett
  • Gapped oligomeric compounds comprising 5?-modified deoxyribonucleosides in the gap and uses thereof
    Patent number: 9752142
    Abstract: The present invention provides gapped oligomeric compounds comprising at least one 5?-substituted P-D-2?-deoxyribonucleoside in the gap region. Certain such gapped oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited to, nucleic acids in a cell. The oligomeric compounds provided herein have improved properties such as selectivity, potency and improved proinflammatory profile. In certain embodiments, hybridization results in modulation of the amount of activity or expression of the target nucleic acid in a cell.
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: September 5, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Michael Oestergaard, Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Antisense compounds and uses thereof
    Patent number: 9714288
    Abstract: The present disclosure provides compounds comprising modified oligonucleotides and anti-CD22 antibodies. Certain such modified oligonucleotides conjugated to anti-CD22 antibodies are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: July 25, 2017
    Assignees: The Regents of the University of California, Ionis Pharmaceuticals, Inc.
    Inventors: Michael Oestergaard, Punit P. Seth, Shuling Guo, Noriko Satake, Nitin Nitin, Joseph M. Tuscano
  • Compositions and methods
    Patent number: 9714421
    Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: July 25, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Oligomeric compounds comprising bicyclic nucleosides and uses thereof
    Patent number: 9695418
    Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell. In certain embodiments, the present invention provides compounds comprising oligonucleotides. In certain embodiments, such oligonucleotides comprise a region having a gapmer sugar motif. In certain embodiments, oligonucleotides comprise one or more type of modified sugar moieties and/or naturally occurring sugar moieties arranged along an oligonucleotide or region thereof in a defined pattern or sugar modification motif.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: July 4, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Susan M. Freier, Brett P. Monia, Eric E. Swayze
  • COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION
    Publication number: 20170183661
    Abstract: Disclosed herein are antisense compounds and methods for decreasing PKK mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate PKK-associated diseases, disorders, and conditions.
    Type: Application
    Filed: May 1, 2015
    Publication date: June 29, 2017
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Susan M. Freier, Huynh-Hoa Bui
  • Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
    Patent number: 9688707
    Abstract: The present invention provides bicyclic morpholino compounds and oligomeric compounds prepared therefrom. More particularly, incorporation of one or more of the bicyclic morpholino compounds into an oligomeric compound is expected to enhance one or more properties of the oligomeric compound. Such oligomeric compounds can also be included in a double stranded composition. In certain embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: June 27, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Eric E. Swayze
  • COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION
    Publication number: 20170166899
    Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, ameliorating a disease associated with excess growth hormone using antisense compounds oligonucleotides targeted to growth hormone receptor (GHR).
    Type: Application
    Filed: May 1, 2015
    Publication date: June 15, 2017
    Applicant: IONIS PHARMACEUTICALS, INC.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Sanjay Bhanot, Susan M. Freier, Huynh-Hoa Bui
  • COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION
    Publication number: 20170159055
    Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.
    Type: Application
    Filed: May 1, 2015
    Publication date: June 8, 2017
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Tamar R. Grossman, Michael L. McCaleb, Andrew T. Watt, Susan M. Freier
  • BICYCLIC CARBOCYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM
    Publication number: 20170145409
    Abstract: The present invention provides novel bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom. Incorporation of one or more of the bicyclic carbocyclic nucleosides into an oligomeric compound is expected to enhance one or more properties of the oligomeric compound. In certain embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in modulation of normal function of the target RNA. In certain embodiments, bicyclic carbocyclic nucleosides are provided as monomers for use as antivirals.
    Type: Application
    Filed: March 17, 2015
    Publication date: May 25, 2017
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Eric E. Swayze
  • COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS
    Publication number: 20170145424
    Abstract: Provided herein are compositions and methods for non-parenteral delivery of conjugated oligomeric compounds. In certain embodiments, compositions and methods are provided for oral delivery of conjugated oligomeric compounds. In certain embodiments, the oligomeric compounds are conjugated to one or more N-acetylgalactosamines or N-acetylgalactosamine analogues.
    Type: Application
    Filed: June 8, 2015
    Publication date: May 25, 2017
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Stanley T. Crooke
  • LINKAGE MODIFIED GAPPED OLIGOMERIC COMPOUNDS AND USES THEREOF
    Publication number: 20170130224
    Abstract: The present invention provides gapped oligomeric compounds. More particularly the gapped oligomeric compounds provided herein comprise at least one modified internucleoside linkage in the gap region. Such gapped oligomeric compounds have one or more improved properties such as selectivity, potency, improved toxicity profile and or improved proinflammatory profile. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.
    Type: Application
    Filed: January 16, 2017
    Publication date: May 11, 2017
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Michael Oestergaard, Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Compounds and methods for modulating gene expression
    Patent number: 9617540
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: April 11, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
  • LINKAGE MODIFIED OLIGOMERIC COMPOUNDS
    Publication number: 20170044526
    Abstract: The present invention provides oligomeric compounds comprising at least one neutral methoxypropyl phosphonate modified internucleoside linkage. Such oligomeric compounds have one or more improved properties such as selectivity, potency, improved toxicity profile and or improved proinflammatory profile. Such oligomeric compounds have enhanced stability to exposure to base during synthesis. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.
    Type: Application
    Filed: April 28, 2015
    Publication date: February 16, 2017
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: W. Brad Wan, Michael T. Migawa, Michael Oestergaard, Eric E. Swayze, Punit P. Seth
  • OLIGOMERIC COMPOUNDS COMPRISING ALPHA-BETA-CONSTRAINED NUCLEIC ACID
    Publication number: 20170044539
    Abstract: The present disclosure provides oligomeric compounds comprising at least one ?-?-constrained nucleic acid as provided herein. More particularly, the ?-?-constrained nucleic acid provided herein comprise an optionally modified nucleoside with a phosphorus containing constrained internucleoside linkage such as for example a cyclic phosphate internucleoside linkage. The ?-?-constrained nucleic acid provided herein are expected to be useful for enhancing one or more properties of oligomeric compounds they are incorporated into such as for example nuclease resistance. In certain embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Application
    Filed: April 24, 2015
    Publication date: February 16, 2017
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Michael Oestergaard, Eric E. Swayze, Punit P. Seth
  • METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS
    Publication number: 20170043025
    Abstract: Provided herein are improved methods for the synthesis of reactive conjugate clusters and intermediates used in such methods. In particular, improvements are provided that enhance the synthesis of reactive conjugate clusters by reducing the number of synthetic steps required. The reactive conjugate clusters prepared using the improved methods don't include any transacylation impurities that are formed using existing methods. The improved methods also provide an increase in overall yield and a cost benefit over existing methods.
    Type: Application
    Filed: May 1, 2015
    Publication date: February 16, 2017
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Michael T. Migawa, Jinghua Yu, W. Brad Wan, Satyen P. Patel, Guillermo Vasquez, Garth A. Kinberger, Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • TARGETED THERAPEUTIC NUCLEOSIDES AND THEIR USE
    Publication number: 20160354476
    Abstract: Provided herein are compounds comprising one or more therapeutic nucleosides and one or more targeting groups. In certain embodiments, the compounds further comprise one or more oligonucleotides. In certain embodiments, a targeting group comprises one or more N-Acetylgalactosamine.
    Type: Application
    Filed: September 19, 2014
    Publication date: December 8, 2016
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Thazha P. Prakash
  • Oligomeric compounds comprising tricyclic nucleosides and methods for their use
    Patent number: 9428750
    Abstract: The present disclosure provides tricyclic nucleosides, oligomeric compounds comprising at least one of the tricyclic nucleosides and methods of using the oligomeric compounds. The methods provided herein include contacting a cell or administering to an animal at least one of the oligomeric compounds. In certain embodiments, the oligomeric compounds hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: August 30, 2016
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Andrew M. Siwkowski, Punit P. Seth, Thazha P. Prakash
  • Cyclohexenyl nucleic acids analogs
    Patent number: 9409934
    Abstract: The present disclosure describes cyclohexenyl nucleic acid analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, cyclohexenyl nucleic acid analogs are provided, having one or more chiral substituents, that are expected to be useful for enhancing properties of oligomeric compounds including nuclease resistance and binding affinity. In some embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: August 9, 2016
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Eric E. Swayze